Halozyme Therapeutics Shares Down 3.3% on Insider Selling (HALO)
Halozyme Therapeutics (NASDAQ:HALO) shares fell 3.3% on Thursday after an insider sold shares in the company, Analyst Ratings Net reports. The stock traded as low as $9.34 and last traded at $9.43, with a volume of 596,344 shares trading hands. The stock had previously closed at $9.75.
Specifically, Director John Stuart Patton sold 75,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $9.96, for a total value of $747,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Separately, analysts at JPMorgan Chase & Co. initiated coverage on shares of Halozyme Therapeutics in a research note on Friday, July 11th. They set an “overweight” rating and a $13.00 price target on the stock. One analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. Halozyme Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $11.13.
The stock has a 50-day moving average of $9.50 and a 200-day moving average of $10.38. The company’s market cap is $1.167 billion.
Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. The company had revenue of $18.40 million for the quarter, compared to the consensus estimate of $13.71 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. The company’s revenue for the quarter was up 27.2% on a year-over-year basis. Analysts expect that Halozyme Therapeutics will post $-0.61 EPS for the current fiscal year.
Halozyme Therapeutics, Inc is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.